Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) has provided an announcement.
Beijing Biostar Pharmaceuticals reported 2025 revenue of RMB33.4 million, down 53.6% year on year, with gross profit halving and a narrowed net loss of RMB131.4 million as the company continued heavy investment in research and development. Despite weaker top‑line performance, monetary funds remained stable and R&D expenses declined, suggesting tighter cost control while sustaining a broad oncology pipeline led by Utidelone in multiple late‑stage clinical programs.
Operationally, the company advanced Utidelone Injection through pivotal registrational trials in breast cancer and lung cancer brain metastasis in the U.S. and China, secured orphan drug designation from the U.S. FDA for first‑line advanced pancreatic cancer, and generated encouraging phase II data in solid tumors such as gastric and esophageal cancers. The oral Utidelone Capsule completed phase I studies in both China and the U.S. and a phase II study in advanced breast cancer in China, demonstrating comparable or better efficacy than the injectable form with notably reduced peripheral neurotoxicity, strengthening Biostar’s competitive position in innovative chemotherapy and its prospects for broader clinical and commercial adoption.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a synthetic biology‑driven biopharmaceutical company focused on developing innovative oncology drugs based on microbial metabolites. Its core commercial product is Utidelone Injection, a first‑in‑class microtubule inhibitor for relapsed or metastatic breast cancer, with an expanding pipeline including new indications and an oral capsule formulation targeted at domestic and international markets.
Average Trading Volume: 40,686
Technical Sentiment Signal: Sell
Current Market Cap: HK$823.5M
For detailed information about 2563 stock, go to TipRanks’ Stock Analysis page.